Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

Cited In for PubMed (Select 12512034)

1.

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC).

Nat Commun. 2015 Mar 5;6:6422. doi: 10.1038/ncomms7422.

2.

Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data.

Konerman MA, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK.

Hepatology. 2015 Jun;61(6):1832-41. doi: 10.1002/hep.27750. Epub 2015 Mar 20.

PMID:
25684666
3.

Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study.

Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB.

PLoS One. 2014 Nov 4;9(11):e111912. doi: 10.1371/journal.pone.0111912. eCollection 2014.

4.

Inflammatory response of endothelial cells to hepatitis C virus recombinant envelope glycoprotein 2 protein exposure.

Urbaczek AC, Ribeiro LC, Ximenes VF, Afonso A, Nogueira CT, Generoso WC, Alberice JV, Rudnicki M, Ferrer R, Fonseca LM, Costa PI.

Mem Inst Oswaldo Cruz. 2014 Sep;109(6):748-56. Epub 2014 Sep 9.

5.

Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression.

Konerman MA, Yapali S, Lok AS.

Aliment Pharmacol Ther. 2014 Oct;40(8):863-79. doi: 10.1111/apt.12921. Epub 2014 Aug 28. Review.

PMID:
25164152
6.

Cell death and cell death responses in liver disease: mechanisms and clinical relevance.

Luedde T, Kaplowitz N, Schwabe RF.

Gastroenterology. 2014 Oct;147(4):765-783.e4. doi: 10.1053/j.gastro.2014.07.018. Epub 2014 Jul 18. Review.

PMID:
25046161
7.

The molecular prevalence of viral infections in transplant candidates with bone marrow suppression, shiraz, southern iran, 2010.

Mohammadi B, Yaghobi R, Dehghani M, Behzad Behbahani A.

Int J Organ Transplant Med. 2013;4(2):87-94.

8.

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24. Review.

PMID:
24768810
9.

Plasma sphingolipids as potential indicators of hepatic necroinflammation in patients with chronic hepatitis C and normal alanine aminotransferase level.

Li JF, Qu F, Zheng SJ, Ren JY, Wu HL, Liu M, Liu H, Ren F, Chen Y, Zhang JL, Duan ZP.

PLoS One. 2014 Apr 15;9(4):e95095. doi: 10.1371/journal.pone.0095095. eCollection 2014.

10.

Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Galati G, Picardi A.

World J Gastroenterol. 2014 Mar 21;20(11):2825-38. doi: 10.3748/wjg.v20.i11.2825. Review.

11.

HCV and HIV co-infection: mechanisms and management.

Chen JY, Feeney ER, Chung RT.

Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):362-71. doi: 10.1038/nrgastro.2014.17. Epub 2014 Feb 18. Review.

12.

The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.

Korean Society for AIDS.

Infect Chemother. 2013 Dec;45(4):455-61. doi: 10.3947/ic.2013.45.4.455. Epub 2013 Dec 27. Review.

13.

Distinct features in natural history and outcomes of acute hepatitis C.

Bunchorntavakul C, Jones LM, Kikuchi M, Valiga ME, Kaplan DE, Nunes FA, Aytaman A, Reddy KR, Chang KM.

J Clin Gastroenterol. 2015 Apr;49(4):e31-40. doi: 10.1097/MCG.0000000000000076.

14.

Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma.

Sakurai T, Kudo M.

Liver Cancer. 2013 Aug;2(3-4):365-6. doi: 10.1159/000343851. No abstract available.

15.

Impact of rural residence and health system structure on quality of liver care.

Rongey C, Shen H, Hamilton N, Backus LI, Asch SM, Knight S.

PLoS One. 2013 Dec 26;8(12):e84826. doi: 10.1371/journal.pone.0084826. eCollection 2013.

16.

Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C.

Behairy BE, El-Mashad GM, Abd-Elghany RS, Ghoneim EM, Sira MM.

World J Hepatol. 2013 Aug 27;5(8):445-51. doi: 10.4254/wjh.v5.i8.445.

17.

Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages.

Shrivastava S, Mukherjee A, Ray R, Ray RB.

J Virol. 2013 Nov;87(22):12284-90. doi: 10.1128/JVI.01962-13. Epub 2013 Sep 4.

18.

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner DE, Liang TJ, Ghany MG.

Hepatology. 2013 Nov;58(5):1548-57. doi: 10.1002/hep.26506. Epub 2013 Sep 30.

19.

Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients.

Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd.

J Clin Gastroenterol. 2013 May-Jun;47(5):457-60. doi: 10.1097/MCG.0b013e318266fe70.

20.

p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.

Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, Karin M.

Cancer Res. 2013 Jan 1;73(1):215-24. doi: 10.1158/0008-5472.CAN-12-1602. Epub 2012 Dec 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk